Preview Mode Links will not work in preview mode

Psychopharmacology and Psychiatry Updates

May 22, 2022

This episode discusses the course and prognosis for stimulant use disorder as well as how to diagnose and assess this disorder. It also explains the loss of control over stimulant use, dysfunctional behaviors, co-occurring psychiatric disorders, and medical side effects. 

Faculty: Andrew Saxon, M.D.
Host: Jessica Diaz,...

May 17, 2022

Should zuranolone be a first-line treatment for postpartum depression? In this episode, Dr. Phelps discusses a randomized trial of zuranolone—a new neuromodulatory steroid—in the context of previous guidelines for the treatment of postpartum depression. 

Faculty: Jim Phelps, M.D. 
Host: Jessica Diaz, M.D.

May 12, 2022

How long should we continue antipsychotic treatment in FEP? This episode discusses the long-term treatment of FEP, including the duration of antipsychotic treatment and the effects of dose reduction, the pros and cons of antipsychotic treatment, and the importance of collaborative treatment. 

Faculty: Stephen Marder,...

May 7, 2022

In this episode, Dr. Phelps discusses the recent literature on brain volume changes after first-episode psychosis. What causes brain volume reductions—the illness or antipsychotics? 

Faculty: Jim Phelps, M.D. 
Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D.

May 2, 2022

Do people with schizophrenia already have a high risk of metabolic effects early in the course of illness?

This episode discusses health concerns for first-episode patients, including life expectancy, metabolic conditions in drug-naïve patients, the signs of developing insulin resistance, and the approaches for early...